Confo Therapeutics Enters Collaborative Agreement with Regeneron

Confo will work together with Regeneron to apply its GPCR drug discovery platform to enable functional antibody discovery Ghent, Belgium – November 30, 2021 – Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron...

CatalYm Presents Updated Tolerability and Preliminary Pharmacodynamics Data from GDF-15 targeting First-in-Human Clinical Trial in Plenary Session at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics

Munich, Germany, October 11, 2021 – CatalYm, today announced an update from the dose escalation part of the ongoing first-in-human trial “GDFather” (GDF-15 Antibody-mediated Effector cell Relocation) investigating its lead product candidate, CTL-002, both in...

Third ADC with Synaffix’s Technology Enters Clinical Development

AMSTERDAM, NETHERLANDS, September 29, 2021 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that its...